Addrenex submits a sNDA to the FDA for Clonicel Sciele Pharma.

Addrenex submits a sNDA to the FDA for Clonicel Sciele Pharma, Inc., a Shionogi firm, and Addrenex Pharmaceuticals today announced that Addrenex provides submitted a supplemental New Medication Application to america Food and Drug Administration for Clonicel to treat attention deficit hyperactivity disorder . In multi-middle, placebo-controlled, double-blind, randomized Stage III scientific trials, Clonicel showed statistical significance when used to treat ADHD.The scientific events committee assessed all lesions in a random sample of 10 percent of enrolled patients, and the results of their assessment were found in analyses of the proportion of lesions that were treated successfully, the proportion of patients in whom the procedure was successful, the proportion of patients with complete revascularization, and the proportion of lesions that were judged to possess met the criteria for class I or II recommendations in the PCI guidelines regarding anatomical indications for PCI.16 Successful treatment of the lesion was thought as residual stenosis of the prospective lesion of less than 20 percent; procedural success was thought as residual stenosis of the mark lesion of less than 20 percent no occurrence of in-hospital major adverse cardiac events.